Efficient drug research with Tecan’s Freedom EVO® 75

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The pharmacokinetic testing laboratory at Toa Eiyo, a Japanese pharmaceutical company specializing in cardiovascular diseases, is using Tecan’s Freedom EVO 75 to achieve greater efficiency though automated sample preparation. Dr Yoshiaki Watanabe, a chief research scientist at Toa Eiyo’s Fukushima Research Laboratories, explained: “Our section conducts pharmacokinetic, toxicity and safety testing on promising candidate compounds for drug development. We wanted to automate several sample preparation steps to achieve greater efficiency, and selected Tecan’s Freedom EVO 75 with an integrated 8 Plus 1 Access™ liquid handling arm for precision pipetting.”

 

“The characteristics of the Freedom EVO make it easy to use for many researchers. Even without specialist knowledge, it is very easy to write a script in the instrument’s operating software, Freedom EVOware®, or adapt existing programs with just a few changes. Installation of an automated pipetting device for pre-clinical and clinical testing has been very welcome, helping to reduce the burden of routine manual tasks, and we anticipate a far-reaching effect of its use in our future research themes.”

 

To find out more on Tecan’s Freedom EVO 75, visit www.tecan.com/freedomevo75 

 

 

 

For more information about Tecan, please contact:

 

 

 

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. With its subsidiary REMP (www.remp.com), Tecan is the market leader in automated laboratory storage and logistics systems. Its clients include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2008, Tecan generated sales of CHF 396 million (USD 366.7 million; EUR 250.7 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).